A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Andrew BlauveltC LeonardiBoni E ElewskiJ J CrowleyL C GuentherMelinda J GooderhamR G LangleyRonald B VenderAndreas PinterC E M GriffithsY TadaH ElmaraghyR G LimaG GalloL RendaRussel T BurgeS Y ParkB ZhuKim A Pappnull nullPublished in: The British journal of dermatology (2020)
Ixekizumab was noninferior to guselkumab in complete skin clearance and superior in clearing nails at week 24. Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, the safety findings were consistent with the known safety profile for ixekizumab.